U.S. to impose 100% tariff on branded, patented drugs unless firms build plants locally

Mathrubhumi English – Trump threatens 100% import tax on pharmaceutical drugs

Trump announced a 100% tariff on branded and patented drugs not manufactured in the U.S.
Pharmaceutical companies can avoid the tariff if they are actively building production facilities in America.
The move is part of a broader push to boost domestic manufacturing and reduce reliance on foreign imports.

CNBC – U.S. to impose 100% tariff on branded, patented drugs

The tariff targets pharmaceutical firms that manufacture outside the U.S. and sell branded drugs domestically.
Exemptions apply to companies with ongoing construction of U.S.-based facilities.
Trump framed the policy as a way to protect American jobs and reduce drug prices.

Free Press Journal – What It Means For Indian Drugmakers

Indian drugmakers like Sun Pharma and Wockhardt may face challenges if they export patented drugs to the U.S.
Generic drugs are mostly exempt from the tariff, offering some relief to Indian exporters.
The policy could shift investment strategies toward U.S.-based manufacturing.

Moneycontrol – Generic medicines exempted, but uncertainty continues

Generic medicines are currently excluded from the 100% tariff, but future policy changes may include them.
A Section 232 investigation could expand the scope of tariffs to cover more drug categories.
Indian pharma stocks showed mixed reactions amid uncertainty over long-term implications.

France24 – Trump slaps 100% tariffs on drugs, trucks and furniture

The 100% tariff applies to imported branded drugs, heavy trucks, and furniture.
Trump emphasized the need to revive U.S. manufacturing and reduce trade deficits.
The announcement is part of a broader trade strategy that may escalate tensions with key trading partners.

Customs